Alinity m HBV

FDA Premarket Approval P200013 S004

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Addition of alternative testing location for a device component

DeviceAlinity m HBV
Generic NameHepatitis Viral B Dna Detection
ApplicantAbbott Molecular, Inc.
Date Received2021-02-05
Decision Date2021-03-08
PMAP200013
SupplementS004
Product CodeMKT 
Advisory CommitteeMicrobiology
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product No
Applicant Address Abbott Molecular, Inc. 1300 E Touhy Ave des Plaines, IL 60018

Supplemental Filings

Supplement NumberDateSupplement Type
P200013Original Filing
S012 2022-12-20 30-day Notice
S011 2022-12-07 Special (immediate Track)
S010
S009 2022-09-21 Special (immediate Track)
S008 2022-05-10 30-day Notice
S007
S006 2022-02-17 30-day Notice
S005 2021-04-15 Real-time Process
S004 2021-02-05 30-day Notice
S003 2021-02-05 30-day Notice
S002
S001 2020-12-21 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.